Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3)

Patients with relapsed/refractory DLBCL may benefit from combination therapy with ibrutinib and loncastuximab tesirine, according to data from an interim analysis of the ongoing phase 2 LOTIS-3 trial presented during the 2021 ASH Annual Meeting. A complete response rate of 34.3% (95% CI: 19.1%-52.2%) was reported, along with a 57.1% overall response rate (95% CI: 39.4%-73.7%), a median duration of response of 5.49 months, and a manageable safety profile consistent with previous studies of this combination therapy.